Unlabelled: Focal nodular hyperplasia (FNH) and adenoma are rare benign hepatic tumors, and the standards for diagnosis and treatment still remain controversial. Usually adenoma is an indication for resection, due to its tendency to bleed and to degenerate; FNH, on the contrary, may be treated conservatively. Preoperation differential diagnosis is, however, difficult, often impossible.
Materials And Methods: Thirty-eight patients with presumed hepatic adenoma and/or FNH were studied at our department from 1984 to 1996. Preoperative assessment included clinical evaluation and symptoms, laboratory tests, liver biopsy, ultrasound scan, computed tomography scan, magnetic resonance imaging, scintigraphy, and angiography. Thirteen patients had a presumed diagnosis of FNH, 16 of adenoma, and 9 of undetermined benign lesions; 27 had hepatic resections (3 with laparoscopic technique), and 11 were not operated on and are actually under a strict follow-up observation.
Results: The final diagnosis was 19 FNH and 19 adenomas (2 of which contained areas of hepatocarcinoma). Presumed diagnosis was confirmed in 71% of cases. Use of oral contraceptives, abdominal symptoms, and pathologic liver test results were frequent in patients with adenomas. There were no deaths after surgery. All resected patients were tumor free during the follow-up, and in 10 of the 11 nonoperated cases, the size of the nodules remained unchanged. We conclude that precise diagnosis of these benign liver tumors remains difficult and sometimes impossible, despite new imaging techniques. Hepatic resections can be performed under very safe conditions; laparoscopic surgery may play a role in selected cases. Adenomas and uncertain cases are clear indications for surgery. Only when a diagnosis of FNH can be firmly confirmed in asymptomatic patients is strict observation without surgery recommended.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/lt.500030209 | DOI Listing |
Quant Imaging Med Surg
December 2024
Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Background: Focal nodular hyperplasia (FNH) in the liver is a benign lesion and the relationship between lesion size and imaging features is yet to be established. We aimed to develop and validate a scoring system to assess the relationship between magnetic resonance imaging (MRI) features and lesion size in FNH.
Methods: This cross-sectional study was conducted at Zhongshan Hospital, Fudan University in Shanghai, China, from August 2019 and March 2023.
Eur Radiol Exp
December 2024
Department of Interventional Ultrasound, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Fengtai District, Beijing, 100853, China.
Background: Noninvasive and functional imaging of the focal liver lesion (FLL) vasculature at microscopic scales is clinically challenging. We investigated the feasibility of using super-resolution ultrasound (SR-US) imaging for visualizing and quantifying the microvasculature of intraparenchymal FLLs.
Methods: Patients with FLLs between June 2022 and February 2023 were prospectively screened.
Ultrasound Q
December 2024
Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN.
Magnetic resonance imaging (MRI) may be time-consuming, expensive, or poorly tolerated by patients with liver lesions. This is a prospective clinical trial designed to evaluate if contrast-enhanced ultrasound (CEUS) can be used to differentiate focal nodular hyperplasia (FNH) from hepatocellular adenoma (HCA) with similar accuracy compared with hepatobiliary agent MRI.Institutional review board approval was obtained (1805450097), and the trial was registered with ClinicalTrials.
View Article and Find Full Text PDFBr J Radiol
November 2024
Department of Radiology, Bursa Uludağ University Faculty of Medicine, Bursa, Turkey.
Objective: To investigate the diagnostic performance of Gd-EOB-enhanced magnetic resonance imaging (MRI) for distinguishing focal nodular hyperplasia (FNH) from hepatocellular adenoma (HCA) in children.
Methods: Twenty-two patients (6 with HCA and 16 with FNH) were retrospectively included in this study. After qualitative analyses of MRI, quantitative analyses were performed by calculating the relative signal intensity ratios (SIR) between lesion and liver parenchyma both on precontrast and hepatobiliary phase images.
Eur Radiol
November 2024
Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Objective: To evaluate gadoxetic acid-enhanced (Gd-EOB-DTPA) MRI features of newly detected benign focal hepatic observations after chemotherapy.
Methods: In this retrospective single-center case-control study, we enrolled a cohort of 43 cancer patients with 93 newly detected benign focal hepatic observations after chemotherapy between January 2010 and December 2020. We evaluated several parameters including the delay of occurrence after chemotherapy, imaging features, and imaging follow-up.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!